drugset
drugset / Trial / NCT06215820

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

NCT06215820 ↗

Phase 3 Completed 410 enrolled Viatris Specialty LLC Mylan Specialty, LP · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after bunionectomy.

Timeline

Start
2023-12-29
Primary completion
2024-08-24
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MR-107A-02 Unknown 15 mg —
Comparator Tramadol Other / unclassified 50 mg —

Indications

No indication recorded.